Condition: EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer · Sponsor: Wayshine Biopharm, Inc.
This study is a multicenter, open label, single-arm phase I/II clinical trial of WSD0922-FU for patients with locally advanced or metastatic non-small cell lung cancer whose disease has progressed with thrid-generation EGFR-TKI .
This description comes directly from the study's public registry record.
lily liu, MD · +8613818880308 · lily.liu@wayshinebiopharm.com
Wei Zhong, PhD · 1-951-547-4692 · wei.zhong@wayshinebiopharm.com
Always discuss trial participation with your own doctor first.
| Anhui Provincial Hospital | Hefei, Anhui, China | Recruiting |
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Recruiting |
| The First Affiliated Hospital, Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
| He'nan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
| Shandong Cancer Hospital | Jinan, Shandong, China | Recruiting |
| Shanghai Chest Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| Shanghai East Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| Shanghai Pulmonary Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| Sichuan Provincial Cancer Hospital | Chengdu, Sichuan, China | Recruiting |
| Tianjin Medical University Cancer Institute and Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
| The First Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Recruiting |
| Taizhou Hospital of Zhejiang Province | Taizhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06631989